Skip to main content
ZYME
NASDAQ Life Sciences

Zymeworks 10-Q Details $173.7M Q3 Profit, $560M Theravance Deal Accounting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$30.81
Mkt Cap
$2.188B
52W Low
$16.003
52W High
$31.49
52W Position info
93% above low
Off High info
2.2% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ZYME sits 93% above its 52-week low of $16.003.

Summary

Zymeworks' Q3 10-Q shows $256.5M of revenue and $173.7M of net income on the $250M Jazz milestone, plus the full accounting for the $560.4M Theravance deal funded with $600M of non-recourse debt.


Key Events · Earnings and Guidance · ZYME

  • Q3 Swing to $173.7M Profit

    Total revenue was $256.5M versus $27.6M a year earlier, including the $250.0M Jazz milestone earned on Ziihera's U.S. first-line GEA approval; net income was $173.7M, or $2.28 per diluted share.

  • Theravance Deal Accounting Booked

    Net consideration paid was $560.4M, allocated to $415.4M of YUPELRI product rights, $96.7M TRELEGY milestone receivable and $104.4M goodwill; Theravance contributed only about $1.5M of revenue for the seven post-closing days.

  • $600M Non-Recourse Financing Stack

    A $250M Royalty Pharma loan (9.7% effective rate, $258.2M net liability) is secured by 30% of Ziihera royalties, and $350M of 8.25% OMERS notes ($338.9M carrying) are serviced by 75% of YUPELRI profit-share cash flows; interest expense on these liabilities was $6.7M in the quarter.

  • Dissenters Open Cayman Appraisal

    Certain former Theravance holders commenced a statutory appraisal action on October 23, 2026; Zymeworks booked $26.3M of deferred consideration at the $17.00 per share deal price, with the ultimate amount still subject to the proceeding.


Analysis · ZYME · Life Sciences

This 10-Q is where the balance sheet actually changed shape, after the 8-K this morning gave only headline numbers. Zymeworks closed the $560.4M net Theravance acquisition on September 23, 2026, booking $415.4M of YUPELRI product rights and $104.4M of goodwill, and funded it with $600M of non-recourse paper: a $250M Royalty Pharma loan against 30% of Ziihera royalties and $350M of 8.25% OMERS notes secured by 75% of YUPELRI profit-share cash flows. That structure is why the company can report a $173.7M quarterly profit and still say it has no plans for equity issuance. The offsetting items are real: interest expense on the sale-of-future-revenue liabilities was $6.7M in the quarter, and dissenting Theravance holders opened a Cayman appraisal action on October 23, 2026, with $26.3M of deferred consideration booked at the $17.00 deal price and the final amount still open.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZYME was trading at $30.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $31.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $31.60 info
Change: +$0.790 (+3%) info
Market Cap: $2.244B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $31.60 info
Change: +$0.790 (+3%) info
Market Cap: $2.244B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $31.60 info
Change: +$3.05 (+11%) info
Market Cap: $2.244B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $31.60 info
Change: +$2.61 (+9%) info
Market Cap: $2.244B info
ZYME
Sep 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $26.52
Real-time Price: $31.60 info
Change: +$5.08 (+19%) info
Market Cap: $2.244B info